Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript

Benzinga APIs supply real-time entree to net telephone transcripts and fiscal data. Visit https://www.benzinga.com/apis/ to larn more.

View the webcast astatine https://viavid.webcasts.com/starthere.jsp?ei=1760798&tp_key=7189f5ac61

Summary

Humacyte Inc reported archetypal 4th 2026 income of Simves astatine $0.5 million, an summation from $0.1 cardinal successful the archetypal 4th of 2025.

The institution is advancing strategical initiatives including the US and planetary commercialized motorboat of Simves, VO12 Phase 3 proceedings successful dialysis access, and a caller quality survey of CTEV successful coronary artery bypass grafting.

Significant organizational changes see caller hires successful elder commercialized and objective roles to accelerate Simves adoption and a workforce restructuring to trim costs by $14.3 cardinal for the remainder of 2026.

Humacyte Inc submitted a Marketing Authorization Application successful Israel and announced a $1.475 cardinal acquisition committedness from Saudi Arabia, reflecting planetary interest.

The US Department of Defense has allocated backing for the valuation of Humacyte's technology, indicating imaginable for aboriginal subject use.

The institution reported a nett nonaccomplishment of $17.6 cardinal for Q1 2026, attributed chiefly to a alteration successful non-cash income from remeasurement of the contingent earnout liability.

Cash and equivalents stood astatine $48.9 cardinal arsenic of March 31, 2026, with nett currency utilized astatine $2.0 cardinal for the archetypal quarter.

Full Transcript

OPERATOR

Good greeting ladies and gentlemen and invited to the Humacyte First Quarter 2026 Earnings Conference Call. Currently each participants are successful perceive lone mode. Later we'll behaviour a question and reply league and instructions volition travel astatine that time. As a reminder, this league telephone is being recorded. I'll present crook the telephone implicit to Tom Johnson from LifeSci Advisors. Please spell up Tom.

Tom Johnson

Thank you Operator earlier we proceed with the call, I would similar to punctual everyone that definite statements made during this telephone are guardant looking statements nether U.S. national SECurities. These statements are taxable to risks and uncertainties that could origin existent results to disagree materially from humanities acquisition oregon contiguous expectations. Additional accusation concerning factors that could origin existent results to disagree from statements made connected this telephone is contained successful our periodic reports filed with the SEC. The guardant looking statements made during this telephone talk lone arsenic of day hereof and the Company undertakes nary work to update oregon revise guardant looking statements but arsenic as required by law. Information presented connected this telephone is contained successful the property merchandise we issued this greeting and successful our Form 10Q which aft filing whitethorn beryllium accessed from the Investor leafage of the Humacyte website. Joining maine connected today's telephone from Hemacyte are Dr. Laura Nicholson, President and Chief Executive Officer and Dale Sander, Chief Financial Officer and Chief firm improvement officer. Dr. Nicholson volition supply a summary of the company's advancement for the archetypal 4th and successful caller weeks, and Dale volition reappraisal the Company's fiscal results for the 4th ended March 31, 2026. I volition present crook the telephone implicit to Dr. Nicholson. Laura